All In Biotech

Drug Trial Radar · NCT05041101

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase Ib/II Study of Grapiprant (IK-007) and Eribulin Combination Treatment for Metastatic Inflammatory Breast Cancer (mIBC)

Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

6

Actual

Start

Dec 21, 2021

Primary completion

Sep 6, 2024

Study completion Sep 6, 2024

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other places in the body (metastatic). Grapiprant is an anti-inflammatory drug that may prevent tumor growth. Eribulin may block tumor cell growth by stopping tumor cell division. Giving grapiprant and eribulin together may help to control the disease.

Conditions

  • Breast Inflammatory Carcinoma
  • Recurrent Breast Inflammatory Carcinoma
  • Stage IV Breast Inflammatory Carcinoma

Interventions

  • Eribulin MesylateDrug

    Given IV

  • GrapiprantDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Safety of Grapiprant and Eribulin Combination TreatmentTime frame: Up to 21 days from the initial treatment
  2. Determine the Efficacy of Grapiprant and Eribulin Combination TreatmentTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M D Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.